Curia Upgrades Spain API Suites for EU GMP Annex 1
ALBANY, N.Y., May 19, 2026 Curia Global, Inc. has announced the completion of a major upgrade to its aseptic...
Cancer Therapeutics
Advertisement
MEKanistic Clears FDA IND for MTX-531 Cancer Trial
MINNEAPOLIS, Minn., May 19, 2026 MEKanistic Therapeutics has announced that the U.S. Food and Drug Administration (FDA) cleared the...
Bayer’s Sevabertinib Gets FDA Priority Review
BERLIN, Germany, May 18, 2026 Bayer has announced that the U.S. Food and Drug Administration (FDA) granted Priority Review...
BMS and Hengrui Form $15 Billion Drug Development Alliance
SHANGHAI, China and PRINCETON, N.J., May 12, 2026 Hengrui Pharma and Bristol Myers Squibb (BMS) have announced a landmark...
Rigel Expands Oncology Portfolio With VEPPANU Licensing Deal
SOUTH SAN FRANCISCO, Calif., May 12, 2026 Rigel Pharmaceuticals has entered into an exclusive global licensing agreement with Arvinas...
Advertisements
Inhibrx Reports Progress for INBRX-106 in HNSCC Trial
SAN DIEGO – May 8, 2026 Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company focused on oncology and rare diseases,...
Eli Lilly to Acquire Ajax Therapeutics in $2.3B Oncology Deal
INDIANAPOLIS, NEW YORK & CAMBRIDGE, Mass., April 27, 2026 Eli Lilly and Company has announced a definitive agreement to...
iDEL Therapeutics Raises €9M to Advance Cancer Pipeline
DORTMUND, Germany, March 17, 2026 iDEL Therapeutics announced the successful close of a €9 million seed financing round led...
H&N Cancer Market to Reach $2.6B by 2032
PUNE, India, February 26, 2026 The global head and neck cancer therapeutics market is projected to grow from USD...
DISCO–Amgen License Deal Advances Surfaceome Cancer Therapies
COLOGNE, Germany – January 7, 2026 — DISCO Pharmaceuticals has entered into an exclusive global license agreement with Amgen...
Advertisement
